🎉 M&A multiples are live!
Check it out!

Botanix Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Botanix Pharmaceuticals and similar public comparables like Pharming, Benevolent AI, and Julphar.

Botanix Pharmaceuticals Overview

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia.


Founded

1984

HQ

Australia
Employees

3

Financials

LTM Revenue $8.9M

LTM EBITDA -$17.2M

EV

$450M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Botanix Pharmaceuticals Financials

Botanix Pharmaceuticals has a last 12-month revenue of $8.9M and a last 12-month EBITDA of -$17.2M.

In the most recent fiscal year, Botanix Pharmaceuticals achieved revenue of $0.4M and an EBITDA of -$8.7M.

Botanix Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Botanix Pharmaceuticals valuation multiples based on analyst estimates

Botanix Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.1M $0.4M XXX XXX XXX
Gross Profit n/a $0.1M XXX XXX XXX
Gross Margin NaN% 17% XXX XXX XXX
EBITDA -$5.7M -$8.7M XXX XXX XXX
EBITDA Margin -8706% -2291% XXX XXX XXX
Net Profit -$8.3M -$5.8M XXX XXX XXX
Net Margin -12795% -1521% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Botanix Pharmaceuticals Stock Performance

As of March 17, 2025, Botanix Pharmaceuticals's stock price is AUD 0 (or $0).

Botanix Pharmaceuticals has current market cap of AUD 759M (or $480M), and EV of AUD 712M (or $450M).

See Botanix Pharmaceuticals trading valuation data

Botanix Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$450M $480M XXX XXX XXX XXX $-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Botanix Pharmaceuticals Valuation Multiples

As of March 17, 2025, Botanix Pharmaceuticals has market cap of $480M and EV of $450M.

Botanix Pharmaceuticals's trades at 50.6x LTM EV/Revenue multiple, and -26.2x LTM EBITDA.

Analysts estimate Botanix Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Botanix Pharmaceuticals and 10K+ public comps

Botanix Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $450M XXX XXX XXX
EV/Revenue 70.8x XXX XXX XXX
EV/EBITDA -30.8x XXX XXX XXX
P/E -32.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -23.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Botanix Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Botanix Pharmaceuticals Valuation Multiples

Botanix Pharmaceuticals's NTM/LTM revenue growth is 481%

Botanix Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $3.4M for the same period.

Over next 12 months, Botanix Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Botanix Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Botanix Pharmaceuticals and other 10K+ public comps

Botanix Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 485% XXX XXX XXX XXX
EBITDA Margin -230% XXX XXX XXX XXX
EBITDA Growth 54% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 251% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $3.4M XXX XXX XXX XXX
S&M Expenses to Revenue 55% XXX XXX XXX XXX
G&A Expenses to Revenue 1105% XXX XXX XXX XXX
R&D Expenses to Revenue 301% XXX XXX XXX XXX
Opex to Revenue 2669% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Botanix Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Botanix Pharmaceuticals M&A and Investment Activity

Botanix Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Botanix Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Botanix Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Botanix Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Botanix Pharmaceuticals

When was Botanix Pharmaceuticals founded? Botanix Pharmaceuticals was founded in 1984.
Where is Botanix Pharmaceuticals headquartered? Botanix Pharmaceuticals is headquartered in Australia.
How many employees does Botanix Pharmaceuticals have? As of today, Botanix Pharmaceuticals has 3 employees.
Is Botanix Pharmaceuticals publicy listed? Yes, Botanix Pharmaceuticals is a public company listed on ASX.
What is the stock symbol of Botanix Pharmaceuticals? Botanix Pharmaceuticals trades under BOT ticker.
When did Botanix Pharmaceuticals go public? Botanix Pharmaceuticals went public in 1985.
Who are competitors of Botanix Pharmaceuticals? Similar companies to Botanix Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Botanix Pharmaceuticals? Botanix Pharmaceuticals's current market cap is $480M
What is the current revenue of Botanix Pharmaceuticals? Botanix Pharmaceuticals's last 12-month revenue is $8.9M.
What is the current EBITDA of Botanix Pharmaceuticals? Botanix Pharmaceuticals's last 12-month EBITDA is -$17.2M.
What is the current EV/Revenue multiple of Botanix Pharmaceuticals? Current revenue multiple of Botanix Pharmaceuticals is 50.6x.
What is the current EV/EBITDA multiple of Botanix Pharmaceuticals? Current EBITDA multiple of Botanix Pharmaceuticals is -26.2x.
What is the current revenue growth of Botanix Pharmaceuticals? Botanix Pharmaceuticals revenue growth between 2023 and 2024 was 485%.
Is Botanix Pharmaceuticals profitable? Yes, Botanix Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.